Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Neoplasm Metastasis × Crizotinib × Clear all

Phase

Status

Completed 4 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 3 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Neuroblastoma 1 Neoplasms 1 Neoplasm Metastasis 1 Lymphoma 1 Lung Neoplasms 1 Endometrial Cancer Recurrent 1 Breast Neoplasms 1 Advanced Cancers 1 Adenocarcinoma of Lung 1 ALK or ROS1-positive NSCLC 1

Interventions

pembrolizumab 21 Capecitabine 21 Bevacizumab 20 Gemcitabine 18 Cyclophosphamide 18 Fluorouracil 17 aldesleukin 15 Leucovorin 15 Docetaxel 15 Paclitaxel 13 Nivolumab 13 Irinotecan 13 Radiosurgery 12 Oxaliplatin 12 Interleukin-2 12 fludarabine 10 Drug Therapy 10 Cisplatin 10 Albumin-Bound Paclitaxel 10 fludarabine phosphate 9 Cetuximab 9 Carboplatin 9 Everolimus 8 Doxorubicin 8 Zoledronic Acid 7 Trastuzumab 7 Sunitinib 7 Radiotherapy 7 Celecoxib 7 130-nm albumin-bound paclitaxel 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02074878 2017-08-09

CRIZENT

Baylor Breast Care Center

Phase 1 Terminated

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡